Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as NAKA and SERA. With a market capitalization of $50.09M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against NAKA's 49.70% and SERA's -200.00%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
